Regulations.gov document
Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal
Notice · FDA-2018-N-3091 · posted Dec 13, 2022
Key facts
| Document ID | FDA-2018-N-3091-0003 |
|---|---|
| Title | Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal |
| Document type | Notice |
| Subtype | Notice of Renewal |
| Agency | FDA |
| Docket | FDA-2018-N-3091 |
| Posted | Dec 13, 2022 |
| Federal Register citation | 87 FR 76197 |
| FR document number | 2022-27014 |
| Comment period opens | Dec 13, 2022 |
| Effective date | Dec 13, 2022 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: